Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BMI1 | P35226 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1708075 | 0.77 | TSHR (0.45) | ALDH1A1CNR2CNR1TSHRBMI1 | |
| SCHEMBL1707986 | 0.77 | MAPK1 (0.48) | ALDH1A1TSHR | |
| SCHEMBL1708252 | 0.71 | DHFR (0.41) | ALDH1A1 | |
| SCHEMBL10818327 | 0.70 | SCN9A (0.55) | ALDH1A1GAATSHRBMI1 | |
| SCHEMBL1708119 | 0.68 | L3MBTL1 (0.41) | ALDH1A1HCAR1TSHRBMI1 | |
| SCHEMBL5851500 | 0.66 | TAAR1 (0.60) | ALDH1A1GAA | |
| SCHEMBL6439085 | 0.65 | ESR2 (0.56) | ALDH1A1GAABMI1 | |
| SCHEMBL1708373 | 0.65 | BMI1 (0.40) | ALDH1A1BMI1 | |
| SCHEMBL1708176 | 0.65 | L3MBTL1 (0.38) | ALDH1A1HCAR1TSHR | |
| SCHEMBL13052920 | 0.65 | USP2 (0.52) | ALDH1A1GAACNR2CNR1BMI1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| EP-2440541-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2012-04-18 | — | — | EP | disclosed |
| WO-2010143733-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172351-A1 | NOVEL FUSED CYCLIC COMPOUND AND USE THEREOF | GPR119, INSR, GLP1R | ALDH1A1 3930/4885GAA 3185/4885HCAR1 82/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.